The board has recommended a final dividend payout of Rs 1.50 per share. In FY23, Biocon’s revenue grew almost 37% to Rs 11,174 crore, while its net profit fell nearly 29% to Rs 463 crore. The biosimilars business segment more than doubled its year-on-year revenue to INR2,102 crore in Q4 2022.
One bitcoin bull cuts forecast by half as “cold breeze” blows
Standard Chartered has halved its bitcoin price forecasts for 2025 and 2026, citing weaker demand and a shift toward ETF-driven buying. Analyst Geoff Kendrick now